characteristics. and high-grade lymphomas, high-dose chemotherapy (HDC) with autologous stem cell rescue (SCR) provides adults (ages 18-60 years; median 36) underwent alloBMT for lymphoma after failure of standard chemolong-term disease-free survival in 40-60% of patients who relapse with chemotherapy-sensitive disease, and has been therapy. Twenty-one had NHL and six had HD (nodular sclerosis). Thirteen patients had primary refractory disshown to be superior to conventional salvage chemotherapy alone. 2 Long-term survival for patients with primary refracease or chemotherapy-resistant relapses; two of these had relapsed after autoBMT. Three patients had tory or chemotherapy-resistant disease treated with HDC and autologous SCR, however, is only about 10%.
3
untested relapses (one of them had relapsed after autoBMT), and 11 had chemotherapy-sensitive relapses.
Low-grade lymphomas are indolent disorders with a high rate of response to initial treatment and a median survival Twenty-four received HLA-matched bone marrow from a sibling (one twin); three received haploidentical marduration of 7-9 years. 3 Although aggressive chemotherapy regimens including HDC and autologous SCR in this group row cells. Nine (33%) died from lymphoma. Eleven (41%) died of treatment-related causes. Opportunistic of patients have shown progression-free survival rates of 50%, follow-up has been relatively short. 4, 5 Again, patients infections were a substantial problem leading to eight of these deaths (30%). Six patients (22%) survive free with advanced, recurrent or refractory disease have had a very poor prognosis. of lymphoma 17-70 months post-BMT (median, 56 months); four had had sensitive relapses, one had had Several groups have begun examining the role of allogeneic bone marrow transplantation (alloBMT) for those a resistant relapse, and one had had nontested relapse. Three have chronic GVHD (limited in one; extensive in HD/NHL patients who are younger than 60 years of age and have a suitable HLA (human leukocyte antigen) comtwo). One HD patient who had relapsed after autoBMT remains in remission 19 months after alloBMT. No patible donor. Advantages of alloBMT include hematopoietic rescue with tumor-free marrow, the potential for a therapy-related myelodysplasia has been observed. We conclude that alloBMT has substantial morbidity in graft-versus-lymphoma effect leading to a lower incidence of relapse post-transplantation, and lower rates of therapyheavily pretreated lymphoma patients due to acute toxicity, infections and GVHD. However, 22% of our related leukemia. The few studies that have been performed using alloBMT have reported a 25-35% early mortality HD/NHL patients have had long-term disease-free survival.
rate, with deaths secondary to graft-versus-host disease (GVHD), as well as regimen-related toxicities and infecKeywords: allogeneic marrow transplantation; Hodgkin's; lymphoma tion. 6 However, lower than expected relapse rates have been observed in surviving patients, thus suggesting the possibility of an immune-mediated graft-versus-lymphoma Hodgkin's disease (HD) and non-Hodgkin's lymphoma effect. 7-9 Here, we report our results from a single insti-(NHL) are hematologic malignancies characterized by diftution in a group of 27 adult patients who underwent ferences in their clinical, morphological, and biological alloBMT for relapsed and refractory HD and NHL. Of these three, one had undergone autoBMT for a prior sclerosing Hodgkin's disease. With regard to the source of allogeneic marrow cells, three patients received marrow relapse and had relapsed again 13 months later. This patient did not receive further chemotherapy prior to undergoing from a haplo-identical family member, one patient received marrow from an identical-twin donor, and 23 patients alloBMT and was included in the untested relapse group. Eleven patients had a relapse with chemosensitive disease. received marrow from a 5/6 or 6/6 HLA-matched sibling donor. All patients gave written informed consent and were treated on protocols approved by the University of Chicago Transplant regimens Institutional Review Board.
Three different preparative regimens were used sequentially during the 8-year period. Eight patients received busulfan Definitions and cyclophosphamide: busulfan 4 mg/kg/day on days −8 to −5 and cyclophosphamide 60 mg/kg/day on days −4 Primary refractory disease was defined as less than 50% reduction in the sum of the product of the two greatest and −3. Fourteen patients received busulfan/cyclophosphamide/cytarabine: busulfan 4 mg/kg/day on days perpendicular diameters of measurable lesions despite treatment with a combination chemotherapy regimen that con-−10 to −7, cyclophosphamide 60 mg/kg/day on days −6 and NHL = non-Hodgkin's lymphoma; REAL = revised European-American lymphoma classification; IWF = International Working Formulation. Primary refractory or refractory relapse were defined as Ͻ50% reduction of tumor mass to last salvage therapy. Chemosensitive relapse was defined as Ͼ50% reduction in tumor mass, assessed by computerized tomography and physical examination. −5, followed by cytarabine 1000-1500 mg/m 2 continuously over 48 h on days −3 and −2. Five patients received total body irradiation (TBI) and etoposide: TBI twice daily on days −7 to −3 with 1350 cGy (nine fractions of 150 cGy) plus etoposide 60 mg/kg on day −3. All patients received intrathecal methotrexate 15 mg plus hydrocortisone 50 mg at the beginning of the preparative regimen. Busulfan levels were not performed. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine at 5 mg/kg/day i.v. from day −2 until day +3. Thereafter, the daily 4-h i.v. dose was adjusted to maintain trough blood levels of 200-400 ng/ml. After day 30, patients were usually switched to an equivalent oral dose. Cyclosporine was continued until day 180. Methylprednisolone 0.5 mg/kg/day i.v. was started on Time in years Survival probability day +7 and then increased to 1 mg/kg/day on day +14. After day 30, steroids were tapered over 2 months.
tation for 27 adults with relapsed and refractory Hodgkin's disease or nonHodgkin's lymphoma. was calculated for patients who obtained a clinically documented complete remission after transplantation to first evidence of relapse (an event) or until death from toxicity or any other cause. The statistical significance of the associand no evidence of lymphoma was found in seven. Six patients died as a result of progressive lymphoma within ation between sensitive or refractory disease status and death within 100 days following BMT was assessed using 100 days of alloBMT, and two more patients died from relapse 712 and 721 days after transplantation. One of these Fisher's exact test. All P values reported are two sided. Data were updated and analyzed as of September 1996.
Statistical methods
patients had lymphoblastic lymphoma and the other had Hodgkin's disease. One other patient died of disseminated Herpes zoster infection 14 months after allogeneic transplantation and did not have any evidence of Hodgkin's disResults ease at autopsy. None of the three patients who had haploidentical donors Six of 27 patients (22%) survive free of lymphoma between 17-70 months post-allogeneic BMT with a median followsurvived the immediate post-transplant period due to acute GVHD and infections. The single patient who had a twin up of 4.7 years. The median overall survival was 83 days (Figure 1 ). Of the six surviving patients, four had had sensitransplant died on day 24 from progressive high-grade lymphoma. Of the 23 patients transplanted from sibling donors tive relapses and one had had resistant relapse. One additional surviving patient who had relapsed after autologwho were serologically matched for HLA class I and II antigens, five patients (22%) had a relapse of lymphoma, ous HDC and SCR was considered to have an untested (second) relapse. Four patients had NHL and two patients and six patients (26%) have had long-term disease-free survival. had HD (Tables 2 and 3 ). All surviving patients remain in complete remission. The median survival of patients with Of those patients who have died, 12 had had chemoresistant disease, seven had chemosensitive disease, and two had chemoresistant disease prior to transplant was 67 days vs 539 days in the chemosensitive group (P = 0.035 for loguntested relapses prior to alloBMT. There were notable differences between the two subsets of patients in mortality rank test comparing both survival curves; see Figure 2 ).
Eleven patients died from multiple treatment-related within the first 100 days: death occurred in the first 100 days in 11 of the 13 patients with chemoresistant disease causes, with infection in eight, pulmonary toxicity in four, hepatic veno-occlusive disease in two, and GVHD in four.
but in only two of the 11 patients in the chemosensitive group (P = 0.003, Fisher's exact test). The causes of death Nine of these patients underwent post-mortem examination 
Discussion
Many factors pose significant obstacles to the use of autologous stem cells as a source for hematopoietic rescue following HDC for patients with NHL. As many as 38% of autologous peripheral blood stem cell products may contain contaminating lymphoma cells and thus place patients at greater risk for relapse following reinfusion. 11 For patients with low-grade lymphomas, 50-80% of patients have marrow involvement at presentation, and nearly all patients have marrow involvement at relapse. 12, 13 In addition, some patients have circulating monoclonal B lymphocytes in their peripheral blood which may contribute to relapse postautologous SCR.
14,15 Such concerns have proven to be real methods may reduce the risk of relapse, but their effectiveness has yet to be proven. With regard to HD, about 75% of patients can expect long-term disease-free survival. Chemotherapy failures in the chemoresistant group were equally divided between disease progression and regimen-related toxicity, while in share a poor prognosis and a median survival of only 1.5-2.5 years. 18 In one study of 186 HD patients treated with the chemosensitive group, toxicity was the sole cause of early death. Fungal infections were a major cause of mor-HDC and SCR, 94 patients achieved CR following transplantation. 19 The 3-year progression-free survival was 40% bidity and mortality in our patients. Four patients died from aspergillus infections, and one patient died with dissemiamong those obtaining a CR and 28% among these obtaining a partial response. nated fusarium within the first 100 days.
There were seven deaths altogether in the chemosensitive The outcome following autologous HDC and SCR is poor due to early mortality secondary to infection and early group. Two died in the early post-BMT period (Ͻ100 days), two died from GVHD, and one died a sudden death and late regimen-related toxicities. 5, 6 A growing concern is therapy-related leukemia, reported in 5-15% of surviving 6 months post-BMT. Two died from late complications: one from Varicella zoster 393 days after transplantation and patients after autologous bone marrow transplantation. [20] [21] [22] This secondary malignancy is relatively refractory to treatone from progressive multifocal leukoencephalopathy 540 days after transplantation. Neither had any residual ment and, in most cases, fatal. Thus, the optimal treatment for patients with primary lymphoma.
There have been two late relapses. One patient died from refractory or relapsing lymphoma has yet to be defined. While HDC and autologous SCR carries lower morbidity recurrent Hodgkin's disease 712 days after transplantation. One late death in a patient with chemotherapy-resistant disand mortality rates compared to alloBMT, the risk of relapse remains high, especially for patients with chemoease occurred from relapsed lymphoblastic lymphoma 721 days post-transplantation.
therapy-resistant disease. Several series suggest a lower probability of disease progression for lymphoma patients better among those patients who had had Ͼ50% response following their most recent treatment (ie chemosensitive undergoing alloBMT as compared to autologous SCR, although no randomized studies have been conducted. [7] [8] [9] relapse) than among the patients with primary refractory disease or those who had chemoresistant relapses. In spite One explanation for these results is a graft-versuslymphoma effect. Laboratory experiments support this of the toxicity of alloBMT procedures in this group of heavily pretreated patients, these results can be viewed as hypothesis. Two murine models have identified a role for a T lymphocyte mediated graft-versus-lymphoma effect, encouraging. Reduced toxicity and possibly better survival rates might be achieved if alloBMT were to be performed both in B-cell lymphoma and in Hodgkin's disease. 23 , 24 Anderson et al, 25 summarizing more than two decades earlier in the disease course for patients with relapsed lymphoma who have an HLA-compatible donor. Allogeneic of experience at the University of Washington, compared all patients with HD undergoing alloBMT with those BMT remains a reasonable option for many patients with relapsed malignant lymphoma. undergoing autologous HDC and SCR. There was no statistically significant difference in event-free survival among these patients (22% in the allogeneic group vs 13% in the autologous and syngeneic group, P = 0.9). There was a Acknowledgements trend toward decreased relapse rates in the patients undergoing alloBMT (48 vs 77%, P = 0.06). There was This work was supported in part by a grant from American Physa statistically significant increase in non-relapse mortality icians Fellowship for Medicine in Israel (EJD). We thank the among the alloBMT patients (58 vs 41%, P = 0.047). eneic bone marrow transplants that were reported to the International Bone Marrow Transplant Registry (IBMTR).
The 3-year DFS for this group of patients was 21%. Thirtytwo percent of patients who were in remission after transReferences plantation relapsed within 3 years. This rate is lower than the relapse rates reported following HDC and autologous contributed to the majority of deaths reported (61%). Cho-
